Literature DB >> 16144894

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.

.   

Abstract

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility, along with the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, is included in the evidence synthesis available through the USPSTF Web site (http://www.preventiveservices.ahrq.gov). The recommendation is also posted on the Web site of the National Guideline Clearinghouse (http://www.guideline.gov).

Entities:  

Mesh:

Year:  2005        PMID: 16144894     DOI: 10.7326/0003-4819-143-5-200509060-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  151 in total

1.  Knowledge, Attitudes, and Practice Regarding Genetic Testing and Genetic Counselors in Jordan: A Population-Based Survey.

Authors:  Mamoun Ahram; Majd Soubani; Lana Abu Salem; Haneen Saker; Muayyad Ahmad
Journal:  J Genet Couns       Date:  2015-04-08       Impact factor: 2.537

2.  Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance.

Authors:  Adam H Buchanan; Santanu K Datta; Celette Sugg Skinner; Gail P Hollowell; Henry F Beresford; Thomas Freeland; Benjamin Rogers; John Boling; P Kelly Marcom; Martha B Adams
Journal:  J Genet Couns       Date:  2015-04-03       Impact factor: 2.537

3.  To the editor: the role of prophylactic surgery in cancer prevention.

Authors:  Michael Fatouros; Georgios Baltogiannis
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

4.  Primary care physician management, referral, and relations with specialists concerning patients at risk for cancer due to family history.

Authors:  M E Wood; B S Flynn; A Stockdale
Journal:  Public Health Genomics       Date:  2013-01-17       Impact factor: 2.000

5.  Development and validation of a primary care-based family health history and decision support program (MeTree).

Authors:  Lori A Orlando; Adam H Buchanan; Susan E Hahn; Carol A Christianson; Karen P Powell; Celette Sugg Skinner; Blair Chesnut; Colette Blach; Barbara Due; Geoffrey S Ginsburg; Vincent C Henrich
Journal:  N C Med J       Date:  2013 Jul-Aug

6.  Too many referrals of low-risk women for BRCA1/2 genetic services by family physicians.

Authors:  Della Brown White; Vence L Bonham; Jean Jenkins; Nancy Stevens; Colleen M McBride
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 7.  Personalised risk communication for informed decision making about taking screening tests.

Authors:  Adrian G K Edwards; Gurudutt Naik; Harry Ahmed; Glyn J Elwyn; Timothy Pickles; Kerry Hood; Rebecca Playle
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Exploring reasons for overuse of contralateral prophylactic mastectomy in Canada.

Authors:  J E Squires; S N Simard; S Asad; D Stacey; I D Graham; M Coughlin; M Clemons; J M Grimshaw; J Zhang; J M Caudrelier; A Arnaout
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

9.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Authors:  Priyanka Sharma; Jennifer R Klemp; Bruce F Kimler; Jonathan D Mahnken; Larry J Geier; Qamar J Khan; Manana Elia; Carol S Connor; Marilee K McGinness; Joshua M W Mammen; Jamie L Wagner; Claire Ward; Lori Ranallo; Catherine J Knight; Shane R Stecklein; Roy A Jensen; Carol J Fabian; Andrew K Godwin
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

10.  Cancer genetics service interest in women with a limited family history of breast cancer.

Authors:  Tamara J Somers; Julie C Michael; William M P Klein; Andrew Baum
Journal:  J Genet Couns       Date:  2009-05-14       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.